DrugPatentWatch Database Preview
Ani Pharms Inc Company Profile
What is the competitive landscape for ANI PHARMS INC, and what generic alternatives to ANI PHARMS INC drugs are available?
ANI PHARMS INC has one hundred and fifty-five approved drugs.
There is one US patent protecting ANI PHARMS INC drugs.
Summary for Ani Pharms Inc
| US Patents: | 1 |
| Tradenames: | 90 |
| Ingredients: | 86 |
| NDAs: | 155 |
Drugs and US Patents for Ani Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms Inc | ZONISAMIDE | zonisamide | CAPSULE;ORAL | 077639-002 | Dec 22, 2005 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Ani Pharms Inc | NIZATIDINE | nizatidine | CAPSULE;ORAL | 075461-001 | Jul 8, 2002 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Ani Pharms Inc | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-001 | Mar 12, 2003 | BX | RX | No | No | 6,500,454 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Ani Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ani Pharms Inc | ATACAND | candesartan cilexetil | TABLET;ORAL | 020838-001 | Jun 4, 1998 | 5,703,110 | ➤ Try a Free Trial |
| Ani Pharms Inc | ATACAND HCT | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 021093-003 | May 16, 2008 | 7,538,133*PED | ➤ Try a Free Trial |
| Ani Pharms Inc | BRETHINE | terbutaline sulfate | TABLET;ORAL | 017849-001 | Approved Prior to Jan 1, 1982 | 4,011,258 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ANI PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 16 mg/12.5 mg and 32 mg/12.5 mg | ➤ Subscribe | 2008-06-25 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg, 16 mg and 32 mg | ➤ Subscribe | 2006-12-22 |
| ➤ Subscribe | Tablets | 32 mg/25 mg | ➤ Subscribe | 2009-03-06 |
International Patents for Ani Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1432411 | ➤ Try a Free Trial |
| Norway | 335070 | ➤ Try a Free Trial |
| Austria | 442134 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Ani Pharms Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0030 | France | ➤ Try a Free Trial | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
| 80045 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204 |
| C/GB99/008 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
